Armata Pharmaceuticals share price logo

Armata Pharmaceuticals

AMEX: ARMP

$3.52

+0.21

(+6.34%)

as on

Armata Pharmaceuticals Stock Performance

as on October 3, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $3.32
    $3.55
    downward going graph

    5.68%

    Downside

    0.85%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.08
    $16.34
    downward going graph

    12.50%

    Downside

    364.20%

    Upside

    downward going graph

Armata Pharmaceuticals share price movements today

Previous Close
$3.31
Open
$3.41
Volume
306.8K
Market Cap
$123.1M
Day's Low - High
$3.32 - $3.55
52 Week Low - High
$3.08 - $16.34

Armata Pharmaceuticals Historical Returns

1 Month Return
-36.23 %
3 Month Return
-40.24 %
1 Year Return
+ 12.82 %
3 Year Return
+ 20.96 %
5 Year Return
-2.76 %

Armata Pharmaceuticals Stock Fundamentals & Key Indicators

Check Armata Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$123.1M

EPS (TTM)

-5.3

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.64

Industry PE ratio

-3.02

PEG Ratio

0.01

EBITDA

-169.0M

Revenue (TTM)

3.3M

Profit Margin

68.23%

Return On Equity TTM

89.70%

Armata Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Armata Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Armata Pharmaceuticals image
Armata Pharmaceuticals
Buy$123.1M-2.76%-0.6468.23%0.00%
Revolution Medicines image
Revolution Medicines
StrongBuy$44.1B609.62%-23.340.00%0.00%
Moderna image
Moderna
Neutral$75.4B-44.29%-24.08-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.5B180.98%30.1986.04%0.00%
Regeneron image
Regeneron
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Armata Pharmaceuticals Stock including INR - Dollar returns

The Armata Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Armata Pharmaceuticals investment value today

Current value as on today

₹1,22,460

Returns

₹22,460

(+22.46%)

Returns from Armata Pharmaceuticals Stock

₹12,821 (+12.82%)

Dollar Impact

₹9,639 (+9.64%)

Analyst Recommendation on Armata Pharmaceuticals Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Armata Pharmaceuticals. Average target price of $17.5

Armata Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Armata Pharmaceuticals.

What analysts predicted

79.89%UPSIDE

Target Price

$17.5

Current Price

$3.52

Analyzed by

2 Analysts

High

$20

Target

$17.50

Low

$15

Armata Pharmaceuticals target price $17.5, a slight upside of 79.89% compared to current price of $3.52. According to 2 analysts rating.

Indian Investors' Interest in Armata Pharmaceuticals Stock

Search interest for Armata Pharmaceuticals Stock has increased by 361% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:361% versus previous 30 day period

Armata Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
-
2
1
0
2
-
-
0
2
Gross Profit
0
0
2
0
0
1
-
-
0
1
Operating Income
-10
-11
-9
-10
-8
-6
-7
-13
-8
-10
EBITDA
-22
12
-2
6
-2
-12
-21
-119
-109
81
Interest Expense
1
2
2
3
3
3
4
4
5
6
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-25
8
-5
2
-6
-16
-26
-124
-115
74
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-25
8
-5
2
-6
-16
-26
-124
-115
74
Net Profit Margin
67.18%
0.00%
89.47%
69.23%
23.22%
83.13%
0.00%
0.00%
42.08%
76.45%

Armata Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
-
0
4
5
4
5
4
Gross Profit
0
-1
-1
-13
-15
-29
3
-29
3
Operating Income
-16
-12
-19
-21
-23
-36
-40
-42
-31
EBITDA
-9
-9
-17
-20
-21
-35
-65
-6
-155
Interest Expense
-
-
0
0
0
0
2
10
16
Depreciation
0
1
1
1
1
0
0
1
1
Income Before Tax
-14
-16
-19
-22
-23
-36
-69
-18
-173
Income Tax Expense
-1
0
-
-
-
-
-
-
-
Net Income
-12
-12
-19
-22
-23
-36
-69
-18
-173
Net Profit Margin
-225.22%
0.00%
0.00%
-1655.04%
-347.36%
-535.75%
78.54%
-565.37%
68.78%

Armata Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-25
8
-5
2
-6
-16
-26
-124
-115
74
Operating Cash Flow
-10
-10
-8
-7
-7
-7
-4
-6
-5
-8
Investing Cash Flow
0
-1
0
0
0
0
0
0
0
0
Financing Cash Flow
34
0
0
-
9
-
14
0
0
27
Change in Cash
24
-11
-9
-7
2
-7
10
-6
-5
19

Armata Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-12
-12
-19
-22
-23
-36
-69
-18
-173
Operating Cash Flow
-9
-9
-15
-18
-23
-32
-47
-37
-25
Investing Cash Flow
0
0
2
0
-1
-2
-8
-1
0
Financing Cash Flow
8
12
8
23
25
44
53
34
25
Change in Cash
0
3
-3
4
0
4
-1
-4
0

Global Institutional Holdings in Armata Pharmaceuticals

Check out the Institutions with significant holdings in Armata Pharmaceuticals.

Funds
Holdings
Vanguard
1.50%
VANGUARD INDEX FUNDS
0.95%
iShares
0.94%
Fidelity Concord Street Trust
0.24%
Bridgeway Funds, Inc.
0.11%
See all

Armata Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 23 September

    Wed, 04:35 PM

    -

    Armata Pharmaceuticals secures $3.7M funding from U.S. Department of War for Phase 3 development of AP-SA02.

Insights on Armata Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 789.0K → 2.51M (in $), with an average increase of 68.6% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -124.29M → 74.14M (in $), with an average increase of 131.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 84.3% return, outperforming this stock by 63.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 554.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ARMP stock has moved down by -36.2%

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
OrganisationArmata Pharmaceuticals
Headquarters4503 Glencoe Avenue, Los Angeles, CA, 90066, US
IndustryBiotechnology
CEODeborah L. Birx

Key Management of Armata Pharmaceuticals

Name

Title

Dr. Deborah L. Birx M.D.

CEO & Director

Mr. David D. House

Chief Financial Officer

Dr. Pierre Kyme Ph.D.

Chief Business Officer

Mr. Peter Hubbard

Vice President of Operations

Ms. Bani Tchekanova Ph.D.

Head of Regulatory Strategy & Operations

FAQs

What is Armata Pharmaceuticals share price today?

Armata Pharmaceuticals share price today is $3.52 as on at the close of the market. Armata Pharmaceuticals share today touched a day high of $3.55 and a low of $3.32.

What is the 52 week high and 52 week low for Armata Pharmaceuticals share?

Armata Pharmaceuticals share touched a 52 week high of $16.34 on and a 52 week low of $3.08 on . Armata Pharmaceuticals stock price today i.e. is closed at $3.52,which is 78.46% down from its 52 week high and 14.29% up from its 52 week low.

What is Armata Pharmaceuticals's market capitalisation today?

Armata Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Armata Pharmaceuticals Stock (ARMP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Armata Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Armata Pharmaceuticals Stock (ARMP) from India?

Indian investors can start investing in Armata Pharmaceuticals (ARMP) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Armata Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Armata Pharmaceuticals share’s latest price of $3.52 as on October 3, 2026 at 8:46 am IST, you will get 2.8409 shares of Armata Pharmaceuticals. Learn more about fractional shares .

What are the returns that Armata Pharmaceuticals has given to Indian investors in the last 5 years?

Armata Pharmaceuticals stock has given -2.76% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?